InterveXion Therapeutics develops medications that reduce the impact of human suffering and disease on individuals and communities. InterveXion is focused on antagonist therapies that neutralize toxins in the body and improve patient health.

We are currently using our proprietary technology to produce small molecule haptens that can elicit an antigenic response in the mammalian immune system. These responses allow us to screen and commercialize monoclonal antibodies that can bind small molecules. These haptens can also be delivered to stimulate an immune response as a vaccine against toxic molecules.

InterveXion is developing PCP-mAb for the treatment of PCP abuse and METH-mAb for the treatment of methamphetamine abuse. These therapies are monoclonal antibodies that can "absorb" these toxins in the bloodstream to reduce the acute effects of overdose and can also be used in the chronic setting to help abusers overcome their dependency.

Our team has successfully developed regulatory strategies for the clinical delivery of new patient specific medicines, new biologics and "follow-on" biologics. We have also designed ,constructed and operated c GMP compliant biologics manufacturing facilities.